COVID-19 vaccines of SII, Bharat Biotech approved for restricted use in emergency situation

COVID-19 vaccines of Serum Institue of India and Bharat Biotech have been granted permission for restricted use in emergency situation, said Drugs Controller General of India (DCGI) on Sunday.

“After adequate examination, CDSCO has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situation and permission is being granted to M/s Cadila Healthcare for conduct of the Phase III clinical trial,” said VG Somani, DCGI, during a media briefing today.

“We’ll never approve anything if there is slightest of safety concern. The vaccines are 100 per cent safe. Some side effects like mild fever, pain and allergy are common for every vaccine. It (people may get impotent) is absolute rubbish,” he added.

The SEC of Standard Drug Organisation met on 1st and 2nd Jan and made recommendations in respect of proposal of restructed emergency approval of COVID-19 vaccine of SII, according to DCGI.

SII Pune has submitted safety immunogenisity and efficacy data generated on 23,745 participants aged more than or equal to 18 years or older from overseas clinical studies, he added.

The overall vaccine efficacy was found to be 70.42 per cent. Further SII was granted permission to conduct phase 2/phase 3 clinical trial on 1,600 participants within the country, according to DCGI.

“The firm also submitted the interim safety and immunogenisity data generated from this trial and the data was found comparable from the data from overseas clinical studies,” said Somani.

“After detailed deliberations SEC has recommended for grant of permission for restricted use in emergency situation subject to certain regulatory conditions. The clinical trial ongoing the country by the firm will continue,” he added.

Bharat Biotech has developed a vaccine named covaxin in collaboration with ICMR and National Institute of Virology, from where they received the virus seed strains. This vaccine is developed on Vero cell platform, which has well-established track record of safety and efficacy in the country and globally.


Support Ethical Journalism. Support The Dispatch

The Dispatch is a sincere effort in ethical journalism. Truth, Accuracy, Independence, Fairness, Impartiality, Humanity and Accountability are key elements of our editorial policy. But we are still not able to generate great stories, because we don’t have adequate resources. As more and more media falls into corporate and political control, informed citizens across the world are funding independent journalism initiatives. Here is your chance to support your local media startup and help independent journalism survive. Click the link below to make a payment of your choice and be a stakeholder in public spirited journalism


The Dispatch is present across a number of social media platforms. Subscribe to our YouTube channel for exciting videos; join us on Facebook, Intagram and Twitter for quick updates and discussions. We are also available on the Telegram. Follow us on Pinterest for thousands of pictures and graphics. We care to respond to text messages on WhatsApp at 8082480136 [No calls accepted]. To contribute an article or pitch a story idea, write to us at [email protected] |Click to know more about The Dispatch, our standards and policies